Όλο το DSpace

Εμφάνιση απλής εγγραφής

Plasma Glutathione and Prodromal Parkinson's Disease Probability

dc.creatorCharisis S., Ntanasi E., Stamelou M., Xiromerisiou G., Maraki M., Veskoukis A.S., Yannakoulia M., Kosmidis M.H., Anastasiou C.A., Giagkou N., Dardiotis E., Hadjigeorgiou G., Sakka P., Kouretas D., Stefanis L., Scarmeas N.en
dc.date.accessioned2023-01-31T07:43:14Z
dc.date.available2023-01-31T07:43:14Z
dc.date.issued2022
dc.identifier10.1002/mds.28826
dc.identifier.issn08853185
dc.identifier.urihttp://hdl.handle.net/11615/72531
dc.description.abstractBackground: A decrease in glutathione (GSH) levels is considered one of the earliest biochemical changes in Parkinson's disease (PD). Objective: The authors explored the potential role of plasma GSH as a risk/susceptibility biomarker for prodromal PD (pPD) by examining its longitudinal associations with pPD probability trajectories. Methods: A total of 405 community-dwelling participants (median age [interquartile range] = 73.2 [7.41] years) without clinical features of parkinsonism were followed for a mean (standard deviation) of 3.0 (0.9) years. Results: A 1 μmol/L increase in plasma GSH was associated with 0.4% (95% confidence interval [CI], 0.1%–0.7%; P = 0.017) less increase in pPD probability for 1 year of follow-up. Compared with participants in the lowest GSH tertile, participants in the highest GSH tertile had a 12.9% (95% CI, 22.4%–2.2%; P = 0.020) slower rate of increase of pPD probability for 1 year of follow-up. Conclusion: Plasma GSH was associated with pPD probability trajectories; therefore, it might assist in the identification of individuals who are likely to reach the threshold for pPD diagnosis more rapidly. © 2021 International Parkinson and Movement Disorder Society. © 2021 International Parkinson and Movement Disorder Societyen
dc.language.isoenen
dc.sourceMovement Disordersen
dc.source.urihttps://www.scopus.com/inward/record.uri?eid=2-s2.0-85117792435&doi=10.1002%2fmds.28826&partnerID=40&md5=4cfd762a3e5d2d85784ac18cebee8284
dc.subjectglutathioneen
dc.subjectglutathioneen
dc.subjectArticleen
dc.subjectcognitionen
dc.subjectdata completenessen
dc.subjectdisease associationen
dc.subjectdisease predispositionen
dc.subjectdisease risk assessmenten
dc.subjecteducational statusen
dc.subjectfollow upen
dc.subjecthumanen
dc.subjectillness trajectoryen
dc.subjectlongitudinal studyen
dc.subjectmajor clinical studyen
dc.subjectneurologic disease assessmenten
dc.subjectParkinson diseaseen
dc.subjectprodromal symptomen
dc.subjectprotein blood levelen
dc.subjectscoring systemen
dc.subjectageden
dc.subjectcomplicationen
dc.subjectParkinson diseaseen
dc.subjectparkinsonismen
dc.subjectprobabilityen
dc.subjectprodromal symptomen
dc.subjectAgeden
dc.subjectGlutathioneen
dc.subjectHumansen
dc.subjectParkinson Diseaseen
dc.subjectParkinsonian Disordersen
dc.subjectProbabilityen
dc.subjectProdromal Symptomsen
dc.subjectJohn Wiley and Sons Incen
dc.titlePlasma Glutathione and Prodromal Parkinson's Disease Probabilityen
dc.typejournalArticleen


Αρχεία σε αυτό το τεκμήριο

ΑρχείαΜέγεθοςΤύποςΠροβολή

Δεν υπάρχουν αρχεία που να σχετίζονται με αυτό το τεκμήριο.

Αυτό το τεκμήριο εμφανίζεται στις ακόλουθες συλλογές

Εμφάνιση απλής εγγραφής